Poll: Obesity's a crisis but we want our junk food

WASHINGTON (AP) — We know obesity is a health crisis, or every new year wouldn't start with resolutions to eat better and get off the couch. But don't try taking away our junk food.
Americans blame too much screen time and cheap fast food for fueling the nation's fat epidemic, a poll finds, but they're split on how much the government should do to help.
Most draw the line at policies that would try to force healthier eating by limiting food choices, according to the poll by The Associated Press-NORC Center for Public Affairs Research.
A third of people say the government should be deeply involved in finding ways to curb obesity, while a similar proportion want it to play little or no role. The rest are somewhere in the middle.
Require more physical activity in school, or provide nutritional guidelines to help people make better choices? Sure, 8 in 10 support those steps. Make restaurants post calorie counts on their menus, as the Food and Drug Administration is poised to do? Some 70 percent think it's a good idea.
"That's a start," said Khadijah Al-Amin, 52, of Coatesville, Pa. "The fat content should be put up there in red letters, not just put up there. The same way they mark something that's poisonous, so when you see it, you absolutely know."
But nearly 6 in 10 people surveyed oppose taxes targeting unhealthy foods, known as soda taxes or fat taxes.
And when it comes to restricting what people can buy — like New York City's recent ban of supersized sodas in restaurants — three-quarters say no way.
"The outlawing of sugary drinks, that's just silly," said Keith Donner, 52, of Miami, who prefers teaching schoolchildren to eat better and get moving.
"People should just look at a Big Gulp and say, 'That's not for me.' I think it starts when they are young and at school," he added.
Indeed, while three-quarters of Americans consider obesity a serious health problem for the nation, most of those surveyed say dealing with it is up to individuals. Just a third consider obesity a community problem that governments, schools, health care providers and the food industry should be involved in. Twelve percent said it will take work from both individuals and the community.
That finding highlights the dilemma facing public health experts: Societal changes over recent decades have helped spur growing waistlines, and now a third of U.S. children and teens and two-thirds of adults are either overweight or obese. Today, restaurants dot more street corners and malls, regular-sized portions are larger, and a fast-food meal can be cheaper than healthier fare. Not to mention electronic distractions that slightly more people surveyed blamed for obesity than fast food.
In the current environment, it's difficult to exercise that personal responsibility, said Jeff Levi of the nonprofit Trust for America's Health, which has closely tracked the rise in obesity.
"We need to create environments where the healthy choice becomes the easy choice, where it's possible for people to bear that responsibility," he said.
The new poll suggests women, who have major input on what a family eats, recognize those societal and community difficulties more than men do.
More than half of women say the high cost of healthy food is a major driver of obesity, compared with just 37 percent of men. Women also are more likely than men to blame cheap fast food and to say that the food industry should bear a lot of responsibility for helping to find solutions.
Patricia Wilson, 53, of rural Speedwell, Tenn., says she must drive 45 minutes to reach a grocery store — passing numerous burger and pizza joints, with more arriving every year.
"They shouldn't be letting all these fast-food places go up," said Wilson, who nags her children and grandchildren to eat at home and watch their calories. She recalls how her own overweight grandmother lost both her legs and then her life to diabetes.
More than 80 percent of people in the AP-NORC poll said they had easy access to supermarkets, but just as many could easily get fast food. Another 68 percent said it was easy for kids to purchase junk food on their way to school, potentially foiling diet-conscious caregivers like Wilson, who doesn't allow her grandchildren to eat unhealthy snacks at home.
"If they say they're hungry, they get regular food," she said.
Food is only part of the obesity equation; physical activity is key too. About 7 in 10 people said it was easy to find sidewalks or paths for jogging, walking or bike-riding. But 63 percent found it difficult to run errands or get around without a car, reinforcing a sedentary lifestyle.
James Gambrell, 27, of Springfield, Ore., said he pays particular attention to diet and exercise because obesity runs in his family. He makes a point of walking to stores and running errands on foot two to three times a week.
But Gambrell, a fast-food cashier, said he eats out at least once a day because of the convenience and has changed his order at restaurants that already have begun posting calorie counts. He's all for the government pushing those kinds of solutions.
"I feel that it's a part of the government's responsibility to care for its citizens and as such should attempt to set regulations for restaurants that are potentially harmful to its citizens," he said.
On the other side is Pamela Dupuis, 60, of Aurora, Colo., who said she has struggled with weight and has been diagnosed as pre-diabetic. She doesn't want the government involved in things like calorie-counting.
"They should stay out of our lives," she said.
The AP-NORC Center survey was conducted Nov. 21 through Dec. 14. It involved landline and cellphone interviews with 1,011 adults nationwide and has a margin of sampling error of plus or minus 4.2 percentage points.
Read More..

High School Basketball Star Must Tan to Treat Rare Disease

When the Shawnee High School basketball team is down on the scoreboard, players know to throw the ball to Josh Borelli. Borelli is not only the team's star player, but also the player most adept at overcoming adversity.
Borrelli, a senior at the Medford, N.J., school, has a condition called Mucha-Habermann, an extremely rare skin disorder that causes lesions to develop all over the body.
Borrelli developed the autoimmune disease out-of-the-blue in eighth grade.
"One day I woke up in the eighth grade and I had red lesions all over my body so I went to the doctors," he told ABC News. "It was the first or second case he's seen in his 40 year practice."
According to the NIH, Mucha-Habermann strikes males more often than females and occurs more frequently in children, specifically between the ages of five to 10. Borrelli's father told the Philadelphia Inquirer that he was believed to be the only person in the country to have the disease at the time he was diagnosed.
"This disease is so rare that most dermatologists don't see it in their entire practice," Dr. Doris Day, clinical associate professor of dermatology at New York University Medical, who does not treat Borrelli, told ABC News. "It's something that we read about but don't see."
Borrelli's own case went into remission as he entered high school, only to return at the start of his senior season. This time, his doctor ordered a new treatment in addition to his prescribed medication: daily visits to the tanning salon.
"My dad went with me the first couple of times to the tanning salon because I was a bit nervous," he said of the first of his now-routine eight minutes per day in the tanning booth.
The treatment worked and Borrelli's skin is now smooth, although enhanced with a Coppertone complexion. Doctors say the ultraviolet technique is so effective that Borrelli cannot miss a single day of tanning, especially since the disease can resurface at any time and cause life-threatening complications in adults.
The treatment has not hurt his basketball game. He continues to average nearly 20 points per game and is just two points shy of scoring 1,000 points in his career.
"If anything it's probably helped," Borrelli said. "There's people out there worse off than I am so I'm real lucky."
Borrelli's year-round tan has even inspired his fans to create a tagline of their own, donning "Fear the Tan" t-shirts at the school's basketball games.
"It's a tough situation and it's been very challenging for him but I've seen him rise to the occasion," Borrelli's father, David Borrelli, told ABC News.

Read More..

Racial gaps in access to robotic prostate surgery

NEW YORK (Reuters Health) - Minority and Medicaid cancer patients are less likely to have their prostates removed at hospitals that use robot-assisted surgery, according to a new study that stops short of suggesting the robotic technique represents better care.
"People who are poor - frequently Hispanic, African American or black, and Medicaid patients - tend to get what is considered to be less high-quality care than those who are middle class and wealthy," said Dr. Otis Brawley, chief medical and scientific officer of the American Cancer Society.
But Brawley, who wasn't involved in the new study, also said there is no evidence that removing a prostate with a robot is better than the old-fashioned way, with "open" surgery that requires an incision across a man's stomach.
Those are two of several treatment options available for prostate cancer, including radiation as well as active surveillance, also known as watchful waiting.
The American Cancer Society estimates approximately 250,000 men were diagnosed with prostate cancer in 2012, and about 28,000 died from it.
Despite a lack of evidence showing its superiority, robot-assisted prostate removal has become the predominant method since being approved by the U.S. Food and Drug Administration in 2000, according to the researchers, led by Dr. Simon Kim at the Mayo Clinic in Rochester, Minnesota.
Robotic surgical tools allow doctors to operate through small incisions with the aid of a tiny video camera, an approach that is considered less invasive but also tends to be more expensive.
Kim and his colleagues write in The Journal of Urology that evidence does exist to show that black patients are already less likely to get radiation or to have their prostates removed, but there is less data on whether they and other minorities have equal access to robot-assisted prostate removal.
For the study, Kim's group used two national databases to compare the differences between the approximately 20,500 cancer patients who had their prostates removed at hospitals offering robotic surgery, and the 9,500 who had their surgery at hospitals without robots between 2006 and 2008.
Overall, the researchers found, the proportion of all prostate removals shifted from about 56 percent taking place at hospitals with robots in 2006 to 76 percent in 2008.
They also found that hospitals offering robotic surgery removed more than four times the number of prostates as other hospitals during that time.
That's important because hospitals that remove more prostates tend to report better patient outcomes after surgery.
In addition, black patients were 19 percent less likely to have their surgery at a hospital using robots compared to white patients, and Hispanic patients were 23 percent less likely.
Medicaid patients were also 30 percent less likely to go to a hospital offering robotic surgery, compared to patients with private insurance.
Dr. Michael Barry, who was not involved in the new research but has studied prostate cancer treatment and outcomes, pointed out that the new work shows a gap in who is able to access the hospitals that perform the greatest number of prostate removals.
"The issue here is not access to robot (surgery) but high-volume hospitals," said Barry, a clinical professor of medicine at Boston's Harvard Medical School.
The study authors, who were not available for comment by press time, similarly conclude that gaps in access to robotic surgery hospitals may also indicate limited access to high-volume hospitals.
"More effective health care policies focusing on incentives to provide better access for minorities or for patients primarily insured by Medicaid may reduce disparities in access to high volume hospitals with robotic surgery," they write.
Read More..

Eli Lilly banks on cost controls for higher 2013 profit

Eli Lilly and Co said on Friday it expects profit in 2013 to increase by more than Wall Street had been forecasting, primarily due to cost controls and improved productivity.
Lilly, whose shares were up nearly 4 percent on Friday, said 2013 sales will be flat to a bit higher, despite the loss of patent on its $5 billion-a-year antidepressant, Cymbalta, in December.
The Indianapolis-based drugmaker is coming off a particularly difficult 2012 when sales declined sharply because of competition from cheaper generics.
It expects 2013 earnings to increase to $3.75 to $3.90 per share excluding items, from a forecast of $3.30 to $3.40 per share in 2012. In 2011, its adjusted earnings were $4.41 per share.
Analysts on average forecast earnings of $3.71 for 2013 and $3.36 per share for 2012, according to Thomson Reuters I/B/E/S.
"Overall, it was better than anyone expected," said Barclays Capital analyst Tony Butler. "From an earnings perspective, no one believed that operating expenses would be kept in check."
Morningstar analyst Damien Conover said, "They're cutting costs at a pace that's maybe a little quicker than people were anticipating, and that was one of the reasons for the outperformance in their guidance."
The company said 2013 net profit would benefit from a tax credit that had been pushed into this year because of the late signing of the American Taxpayer Relief Act of 2012 - the legislation that prevented the so-called fiscal cliff.
The company said it is not sure yet of the amount of the tax credit, which is related to research and development accounting, and said it would provide more information during its January 29 earnings conference call. Lilly said it excluded the impact from all of its financial guidance.
Similar uncertainty could face other drugmakers, as well as other corporate sectors with extensive research budgets, such as technology and defense. However, "It could be resolved by the time everybody else reports," Butler said of the pharmaceutical industry. "We've got another three weeks before anyone reports."
Lilly said the adjusted earnings forecast also excludes payment and income for revenue sharing with Bristol-Myers Squibb Co's Amylin unit on Byetta, a diabetes drug, and restructuring charges. Lilly severed ties with Amylin when it agreed to collaborate with Boehringer Ingelheim on diabetes drug development.
HELP ON THE WAY
Lilly forecast 2013 revenue of $22.6 billion to $23.4 billion, driven by sales of its drugs for diabetes, osteoporosis, cancer, erectile dysfunction and animal health. The company said it also expects significant revenue growth from Japan and emerging markets, such as China.
Analysts are looking for 2013 revenue of $22.82 billion.
While Cymbalta is not expected to start facing generic competition until the end of the year, the company cautioned that sales declines could begin sooner if wholesalers start to reduce inventory supplies prior to the patent expiration.
As a result, it said, the fourth quarter could look significantly different than the first three.
Lilly has already been battered by generic competition for its once top-selling schizophrenia drug, Zyprexa, and will face generic competition for its $1 billion-a-year Evista osteoporosis drug in early 2014.
But help is on the way. Lilly said it now has 13 drugs in late-stage testing, the most at any one time in its history. It could seek approvals this year for drugs for Type 1 and Type 2 diabetes, gastric cancer and for a type of lymphoma.
Chief Financial Officer Derica Rice told analysts on a conference call that the company was firmly focused on replenishing the developmental pipeline. "This is our future and it's our first priority."
The company also vowed to maintain its dividend payout and complete its share repurchase plan.
"Lilly has financially done a really good job. Obviously, you need the pipeline to come through," said Barclay's Butler, adding that positive late-stage data on ramucirumab in breast cancer could signal an important new product for Lilly. The drug is also in late-stage testing for the smaller gastric cancer market.
Other key events for Lilly in 2013 include the start of a new Phase III trial of solanezumab in patients with mild Alzheimer's disease after an earlier study failed but showed some signs of hope for the memory-robbing condition, and an August trial challenging a method of use patent on the $3 billion-a-year lung cancer drug Alimta.
Should Lilly prevail in court, the company could have patent protection on the medicine into 2022 even though the basic patent lapses in 2016.
Asked if the company would consider settling the case before it comes to trial, Phil Johnson, Lilly's vice president for investor relations, said: "Nothing is off the table, but we have not historically entered into those kinds of agreements."
Eli Lilly shares were up 3.8 percent at $51.60 on Friday afternoon on the New York Stock Exchange.
Read More..

Researchers Discover New Strategy to Fight Obesity

After decades of achieving little long-term success with medications, Belgian scientists have come up with a new strategy to fight obesity. They're targeting food sensors in the stomach.
Researchers from the Catholic University of Leuven have reported that the digestive tract "tastes" what a person eats. It uses signaling devices similar to those found in the tongue to detect bitter, sweet, fat, and savory taste, according to Medical News Today.
Thanks to these mechanisms, the gut release hormones that control blood sugar levels and feelings of being satisfied once food reaches the stomach. A malfunction in the sensors could have a role in developing obesity-associated illnesses.
The Mayo Clinic offers a simple definition of obesity: having an excessive amount of body fat. This boosts the risk of developing a number of adverse health conditions, among them heart disease, high blood pressure, and diabetes.
A diagnosis of obesity is the result of calculating body mass index (BMI), which considers weight and height. Individuals with a BMI of less than 18.5 are considered underweight. A range of 18.5 to 24.9 is normal. Overweight patients score between 25.0 and 29.9, while a BMI of 30.0 or more signals obesity. The extremely obese score at least 40.0. The National Heart Lung and Blood Institute posts a free BMI calculator on its site.
More than 35 percent of U.S. adults are obese, according to the Centers for Disease Control and Prevention. Medical costs linked to the condition cost a whopping $147 billion in 2008. In 2011, a dozen states had obesity prevalence rates of at least 30 percent: Alabama, Arkansas, Indiana, Kentucky, Louisiana, Michigan, Mississippi, Missouri, Oklahoma, South Carolina, Texas, and West Virginia.
The Belgian researchers reported that an increasing amount of data suggests that obesity and related conditions could be treated or even prevented by targeting taste receptors on gut cells. Causing them to release hormones that make the patient feel full would mirror the effects of eating.
They also suggested that successful bariatric surgeries might somehow be related to a release of hormones in the digestive tract. However, they stress that more studies are necessary to determine which receptors in the gut should be targeted.
I come from a family of obese people. I've tried dozens of times to reach a BMI of less than 25. The longest I succeeded was six months. I am constantly plagued by feelings of hunger, not just appetite. I am not sufficiently overweight to consider surgery, and due to food restrictions linked to Crohn's disease, many so-called healthy snacks like fresh fruits and vegetables are off limits.
I remain in an orbit of being overweight and sometimes obese. Given the lack of success of current medications for obesity and the Crohn's restrictions I have, fooling the body into sensing satiety to fight obesity could provide a valuable treatment.
Read More..

Steve Jobs Film Coming in April

jOBS, the independent film about former Apple CEO Steve Jobs, will arrive in theaters in April, the movie's distributors announced Thursday.
The film -- not to be confused with the one Sony Pictures is creating based on Walter Isaacson's biography of the late tech luminary -- will star Ashton Kutcher as Jobs and is still slated to premiere this month on the closing night of the Sundance Film Festival.
[More from Mashable: ‘Biggest Loser’ Online Hub Gets Makeover for Season 14]
Along with the April release date, distributors Open Road Films and Five Star Feature Films released this deeper synopsis of the jOBS on Thursday:
Directed by Joshua Michael Stern, written by Matthew Whitely, shot by Oscar- winning cinematographer Russell Carpenter and produced by Mark Hulme, jOBS details the major moments and defining characters that influenced Steve Jobs on a daily basis from 1971 through 2000. jOBS plunges into the depths of his character, creating an intense dialogue-driven story that is as much a sweeping epic as it is an immensely personal portrait of Steve Jobs' life. The filmmakers were granted unprecedented access during shooting to the historic garage in Palo Alto, that served as the birthplace to Apple Inc.
[More from Mashable: Which Movie Had the Sloppiest Science in 2012?]
The Sundance Institute shared the jOBS promo image (above) in December. It is a play on this photograph of Jobs on desk during his early Apple days.
Jobs died from pancreatic cancer in October 2011.
Mark Hulme of Five Star describes Kutcher's performance as "inspiring and unforgettable."
Kutcher, who stars in CBS's Two and a Half Men, previously played roles on Fox'sThat '70s Show and in films such as The Butterfly Effect, No Strings Attached, Valentine's Day and Dude, Where's My Car?
SEE ALSO: How Ashton Kutcher Will Look as Steve Jobs in Forthcoming Biopic
jOBS also stars Dermot Mulroney, Josh Gad, Lukas Haas, J.K. Simmons and Matthew Modine. Inferno Entertainment is handling international sales on jOBS.
Steve Jobs demos Apple Macintosh, 1984

Steve Jobs introduces the Macintosh to the world. Computing would never be the same.
Click here to view this gallery.
Read More..

This Is What the OUYA Kickstarter Console Looks Like

The OUYA, the $99 Android console, is indeed smaller than a soda can.
Click here to view this gallery.
[More from Mashable: 10 Killer Cases for the Samsung Galaxy S III]
The $99 hackable Android-based gaming console OUYA is fulfilling its orders for Kickstarter backers by sending the first units out to developers. Backers began receiving their OUYA consoles as early as last Friday.
According to the OUYA blog, 1,200 consoles have been sent out to developers. While these aren't the final run of the OUYA that consumers will receive, they have enough pieces to get developers started making games for the console. Developers receive a rooted console, along with two transparent, prototype controllers specially designed for the console.
[More from Mashable: This Is the Best Soda Drinking Simulator You’ll Play All Week]
The OUYA raised more than $8 million on Kickstarter last summer, promising to open the television to all developers by including an SDK with every console and encouraging users to hack the system.
While questions were raised about whether the OUYA would be able to deliver on time to its Kickstarter backers, releasing the developer unit and API by the end of December met the promise listed on the Kickstarter page.
Game creator Dave Schrader gave Mashable pictures of his developer unit that he received Monday. You can check them out in the gallery above.
Are you excited about or skeptical of the OUYA? Let us know in the comments.
Read More..

Google escapes antitrust suit as FTC ends its investigation into alleged ‘patent abuse’

Good news for Google (GOOG): It will at least avoid an antitrust lawsuit in the United States. The Federal Trade Commission on Thursday formally concluded its investigation into whether Google allegedly abused the patents that it acquired in the Motorola deal to block rival products over technologies that have become industry standards. Google did have to make some key concessions to end the investigation, including giving its competitors access to its FRAND patents, giving “online advertisers more flexibility to simultaneously manage ad campaigns on Google’s AdWords platform and on rival ad platforms,” and refraining “from misappropriating online content from so-called ‘vertical’ websites that focus on specific categories such as shopping or travel for use in its own vertical offerings.” Ending the investigation with only offering voluntary concessions represents a major victory for a company that earlier this year seemed to be headed for an antitrust lawsuit much like the one filed against Microsoft (MSFT) back in 1998.
Read More..

FTC ends long Google probe with mild reprimand

WASHINGTON (Reuters) - Regulators on Thursday closed a long-running investigation of Google with a relatively mild agreement that is likely to disappoint rivals and critics of the Web search giant.
Under the agreement, Google agreed to end the practice of "scraping" reviews and other data from rivals' websites for its own products, and to allow advertisers to export data to independently evaluate advertising campaigns, the Federal Trade Commission said.
FTC Chairman Jon Leibowitz said Google also agreed to license standard patents on fair, reasonable and non-discriminatory terms.
Read More..

It's 'cash only' now for tourists at the Vatican

VATICAN CITY (AP) — It's "cash only" now for tourists at the Vatican wanting to pay for museum tickets, souvenirs and other services after Italy's central bank decided to block electronic payments, including credit cards, at the tiny city-state.
Deutsche Bank Italia, which for some 15 years had provided the Vatican with electronic payment services, said Thursday that the Bank of Italy had pulled its authorization after Dec. 31.
The Corriere della Sera newspaper reported that the Italian central bank took the action because the Holy See has not yet fully complied with European Union safeguards against money laundering. That means Italian banks are not authorized to operate within the Vatican, which is in the process of improving its mechanisms to combat laundering.
The Vatican says it is scrambling to solve the problem for thousands of visitors who flock to its very popular Vatican Museums, which include highlights like the Sistine Chapel. The Holy See had no immediate comment on the Bank of Italy's reported reasons.
Tourists in the long lines Thursday that snaked around Vatican City walls were not happy about the inconvenience.
"It's certainly a disadvantage," said Giuseppe Amoruso, an Italian. "Credit cards provide a useful service, which needs to be accessible to everybody, everywhere."
"A lot of tourists don't have cash on them, so they have to get euros and don't know where to get them," said Fluger William Hunter, an American tourist.
The central bank said a routine inspection found that Deutsche Bank Italia hadn't sought authorization when it first started providing services at the Vatican. When it finally did, the Bank of Italy turned it down because the Vatican's banking norms, including measures to combat money laundering, didn't meet Italy's more stringent criteria of recent years, a central bank official said, speaking on condition of anonymity because there was no official statement on the case.
The Vatican has been striving to upgrade its measures to detect and discourage money laundering, hiring a Swiss expert just a few months ago. Last summer, the Holy See passed a key European financial transparency test but received failing grades for its financial watchdog agency and its bank, formally called the Institute for Religious Works.
The museums, with their entrance fees and popular souvenir shops, are a big money-maker for the Vatican. Other Vatican attractions, such as tours of the Vatican's ancient underground spaces, also charge admission.
Read More..